Should I buy or sell GeoVax Labs stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GOVX shares. View GOVX analyst ratings or view top-rated stocks .

What is GeoVax Labs' stock price target for 2024?

1 equities research analysts have issued 12 month price targets for GeoVax Labs' shares. Their GOVX share price targets range from $120.00 to $120.00. On average, they predict the company's share price to reach $120.00 in the next year. This suggests a possible upside of 8,119.2% from the stock's current price. View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts .

How have GOVX shares performed in 2024?

GeoVax Labs' stock was trading at $5.4150 at the start of the year. Since then, GOVX shares have decreased by 73.0% and is now trading at $1.46. View the best growth stocks for 2024 here .

Are investors shorting GeoVax Labs?

GeoVax Labs saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,600 shares, a decline of 60.2% from the March 15th total of 16,600 shares. Based on an average daily trading volume, of 40,100 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the company's shares are sold short. View GeoVax Labs' Short Interest .

When is GeoVax Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our GOVX earnings forecast .

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) posted its earnings results on Thursday, March, 23rd. The company reported ($3.00) EPS for the quarter, missing analysts' consensus estimates of ($2.55) by $0.45. During the same period in the prior year, the company posted ($33.60) EPS.

When did GeoVax Labs' stock split?

GeoVax Labs's stock reverse split before market open on Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of GeoVax Labs?

Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GOVX

GeoVax Labs (GOVX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free GOVX Stock Alerts

$1.46

-0.07 (-4.58%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.45
▼
$1.68
50-Day Range: $1.46
▼
$2.71
52-Week Range: $1.45
▼
$11.54

Volume: 28,812 shs
Average Volume: 37,988 shs
Market Capitalization: $3.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $120.00

Get GeoVax Labs alerts:

GeoVax Labs MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 8,119.2% Upside
$120.00 Price Target
Short Interest: Healthy
0.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$1,118 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
GeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
GeoVax Labs has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.31% of the float of GeoVax Labs has been sold short.
Short Interest Ratio / Days to Cover
GeoVax Labs has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GeoVax Labs has recently decreased by 60.24%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
GeoVax Labs does not currently pay a dividend.
Dividend Growth
GeoVax Labs does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GOVX.

2.4

News and Social Media Coverage

News Sentiment
GeoVax Labs has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for GeoVax Labs this week, compared to 1 article on an average week.
Search Interest
5 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,118.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.00% of the stock of GeoVax Labs is held by insiders.
Percentage Held by Institutions
Only 6.09% of the stock of GeoVax Labs is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of GeoVax Labs is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GeoVax Labs is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GeoVax Labs has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About GeoVax Labs Stock (NASDAQ:GOVX)

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GOVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GOVX Stock News Headlines

April 17, 2024 | americanbankingnews.com

GeoVax Labs (NASDAQ:GOVX) Stock Price Down 4.8%

April 13, 2024 | americanbankingnews.com

GeoVax Labs (NASDAQ:GOVX) and Biomea Fusion (NASDAQ:BMEA) Head to Head Review

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 5, 2024 | finanznachrichten.de

GeoVax, Inc.: GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

March 28, 2024 | globenewswire.com

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

March 22, 2024 | investing.com

GeoVax Labs Inc (GOVX)

March 12, 2024 | globenewswire.com

GeoVax to Present at the 36th Annual Roth Conference

March 6, 2024 | globenewswire.com

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 2, 2024 | finance.yahoo.com

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript

March 1, 2024 | finanznachrichten.de

GeoVax, Inc.: GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

February 29, 2024 | globenewswire.com

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

February 28, 2024 | benzinga.com

Earnings Outlook For Geovax Labs

February 24, 2024 | msn.com

GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78

February 23, 2024 | msn.com

InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

February 22, 2024 | finance.yahoo.com

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

February 22, 2024 | globenewswire.com

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

February 20, 2024 | finance.yahoo.com

GeoVax Labs, Inc. (GOVX)

February 20, 2024 | uk.finance.yahoo.com

GeoVax to Present at the 2024 BIO CEO & Investor Conference

February 19, 2024 | finance.yahoo.com

GeoVax to Present at the 2024 BIO CEO & Investor Conference

February 19, 2024 | globenewswire.com

GeoVax to Present at the 2024 BIO CEO & Investor Conference

January 29, 2024 | msn.com

GeoVax Labs to effect 1-for-15 reverse stock split to regain compliance with Nasdaq rule

January 8, 2024 | finanznachrichten.de

GeoVax, Inc.: GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

January 8, 2024 | finance.yahoo.com

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

November 30, 2023 | finance.yahoo.com

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

November 29, 2023 | finance.yahoo.com

GeoVax to Participate in Upcoming December Investor Events

November 28, 2023 | finance.yahoo.com

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

See More Headlines

Receive GOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/23/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GOVX
CUSIP: N/A
CIK: 832489
Web: www.geovax.com
Phone: (678) 384-7220
Fax: 678-384-7281
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $120.00
High Stock Price Target: $120.00
Low Stock Price Target: $120.00
Potential Upside/Downside: +8,119.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($13.3434)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -189.16%
Return on Assets: -140.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.24
Quick Ratio: 2.24

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 39.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.24 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: 2,170,000
Free Float: 2,085,000
Market Cap: $3.17 million
Optionable: Not Optionable
Beta: 2.89

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. David Alan Dodd (Age 74)
Chairman, President & CEO
Comp: $384.2k
Dr. Mark J. Newman Ph.D. (Age 69)
Chief Scientific Officer
Comp: $291.5k
Dr. Kelly T. McKee Jr. (Age 73)
M.D., M.P.H., Chief Medical Officer
Comp: $361.03k
Dr. Harriet Latham Robinson Ph.D. (Age 86)
Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board
Mr. Thomas O'Brien
Vice President of Quality Systems & Compliance
Mr. Jeffrey Welch
Head of Process Development & Manufacturing Operations
Dr. Valerie C. Montgomery Rice FACOG (Age 61)
M.D., Special Advisor to the Chairman & CEO and Board of Directors
Mr. John Niles
Head of Commercial Operations
Dr. John W. Sharkey Ph.D. (Age 68)
Vice President of Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GOVX Stock Analysis - Frequently Asked Questions

Should I buy or sell GeoVax Labs stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GOVX shares.
View GOVX analyst ratings or view top-rated stocks.
What is GeoVax Labs' stock price target for 2024?: 1 equities research analysts have issued 12 month price targets for GeoVax Labs' shares. Their GOVX share price targets range from $120.00 to $120.00. On average, they predict the company's share price to reach $120.00 in the next year. This suggests a possible upside of 8,119.2% from the stock's current price.
View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts.
How have GOVX shares performed in 2024?: GeoVax Labs' stock was trading at $5.4150 at the start of the year. Since then, GOVX shares have decreased by 73.0% and is now trading at $1.46.
View the best growth stocks for 2024 here.
Are investors shorting GeoVax Labs?: GeoVax Labs saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,600 shares, a decline of 60.2% from the March 15th total of 16,600 shares. Based on an average daily trading volume, of 40,100 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the company's shares are sold short.
View GeoVax Labs' Short Interest.

When is GeoVax Labs' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our GOVX earnings forecast.
How were GeoVax Labs' earnings last quarter?: GeoVax Labs, Inc. (NASDAQ:GOVX) posted its earnings results on Thursday, March, 23rd. The company reported ($3.00) EPS for the quarter, missing analysts' consensus estimates of ($2.55) by $0.45. During the same period in the prior year, the company posted ($33.60) EPS.
When did GeoVax Labs' stock split?: GeoVax Labs's stock reverse split before market open on Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
How do I buy shares of GeoVax Labs?: Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GOVX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GeoVax Labs (GOVX) Stock Price, News & Analysis

GeoVax Labs MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GeoVax Labs Stock (NASDAQ:GOVX)

GOVX Stock Price History

GOVX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GOVX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™